XLV, the Health Care Select Sector SPDR ETF, is sending a cleaner signal this week — options positioning has swung sharply toward bullish sentiment even as the short rebuild from earlier in May shows signs of stalling.
The most striking development is in the options market. Put/call ratio has collapsed to 1.30, nearly two standard deviations below its 20-day mean of 1.96 — the most bullish options read in weeks. A fortnight ago, that ratio sat above 2.10 as healthcare traders loaded up on downside protection. The reversal is abrupt. Earlier in May, the PCR was running near its 52-week high of 2.67, reflecting genuine fear around the sector. Now it's trending toward the low end of its annual range, suggesting the defensive hedging that dominated April and early May has been unwound aggressively.
The short positioning story is evolving too, and in a different direction from that options signal. Short interest has crept up further to 3.86% of the float — about 10 million shares — up nearly 5% on the week. That's a continuation of the rebuild documented in the previous note, but the pace has cooled considerably. The previous article flagged a 27% jump in five days; this week's follow-through is a much more modest 4.7%. Borrow costs ticked up to 0.51% — a new recent high and up 6% on the week — but remain trivially cheap in any absolute sense. What has changed dramatically is borrow availability: it has loosened sharply, more than doubling over the past week to 785%. A reading above 200% signals a comfortable lending market, and 785% is unambiguously loose. Shorts face no friction accessing new positions, yet they appear to be adding cautiously rather than aggressively. The short score has drifted back down to 36.4 from a peak of 41.0 on May 12, confirming the deceleration in bearish momentum.
Price has recovered with the options turn. XLV closed at $147.32, up 1.1% on the day and just over 1% on the week — a meaningful stabilisation after the fund shed nearly 1% over the past month. The recent note described the ETF as stuck near $145.85; it has since added over a dollar, closing near a level that brings it back into the range where shorts built in mid-April before the April liquidation. The sector narrative continues to favour defensive rotation. Large-cap pharma and medical device names are leading flows as macro uncertainty pushes capital toward healthcare's relative earnings stability.
On the institutional side, the March-end filings show JPMorgan trimmed its XLV position by nearly 970,000 shares, and Raymond James cut by 187,000. Against that, Goldman Sachs added 251,000 shares and La Caisse de dépôt built by 666,000 — one of the larger incremental buys in the top-15. The picture is mixed rather than directional, with larger broker-dealers taking off exposure while some long-term allocators added. No single dominant flow stands out.
The divergence to watch heading into the final weeks of May is the gap between what options traders and short sellers are signalling: puts are being abandoned at the fastest clip in months, while short positions are quietly edging higher. Which of those reads the sector more accurately is the question framing XLV's near-term setup.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
